Cellular lipid oxidation ratio using BODIPY-C11 in A-498 (left) or Karpas299 (right) UGDH _KO cell lines expressing a sgRNA resistant UGDH cDNA under GPX4 inhibition (ML162: 200 nM for Karpas299, 250 nM for A-498) and Fer-1 supplementation (1 M)
No real results to report yet-stay tuned
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
This combination speeds evaluation, reduces unnecessary trips, and provides a second opinion that can be taken to an in-person provider if further testing is necessary
We accept payments utilizing HSA, FSA, and all major credit or debit cards
The proprietary composition reflects an evidence-based approach to formulation design, drawing upon published scientific literature to identify peptide sequences with complementary mechanisms of action